Lynch Asset Management Inc. Increases Stake in Novo Nordisk A/S (NYSE:NVO)

Lynch Asset Management Inc. boosted its holdings in Novo Nordisk A/S (NYSE:NVO) by 0.6% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 106,950 shares of the company’s stock after purchasing an additional 650 shares during the quarter. Novo Nordisk A/S makes up about 3.7% of Lynch Asset Management Inc.’s investment portfolio, making the stock its 5th largest holding. Lynch Asset Management Inc.’s holdings in Novo Nordisk A/S were worth $9,200,000 as of its most recent SEC filing.

Several other institutional investors have also recently added to or reduced their stakes in NVO. Natixis Advisors LLC boosted its position in Novo Nordisk A/S by 2.7% during the 3rd quarter. Natixis Advisors LLC now owns 3,074,876 shares of the company’s stock valued at $366,125,000 after purchasing an additional 80,070 shares during the period. Norman Fields Gottscho Capital Management LLC lifted its stake in Novo Nordisk A/S by 45.3% in the fourth quarter. Norman Fields Gottscho Capital Management LLC now owns 63,732 shares of the company’s stock valued at $5,482,000 after buying an additional 19,870 shares during the last quarter. Versant Capital Management Inc acquired a new position in shares of Novo Nordisk A/S during the fourth quarter valued at $86,000. Talbot Financial LLC bought a new position in shares of Novo Nordisk A/S during the fourth quarter worth about $4,066,000. Finally, Zions Bancorporation N.A. increased its holdings in shares of Novo Nordisk A/S by 57.0% in the 3rd quarter. Zions Bancorporation N.A. now owns 18,535 shares of the company’s stock worth $2,207,000 after acquiring an additional 6,726 shares during the period. Institutional investors own 11.54% of the company’s stock.

Novo Nordisk A/S Price Performance

Shares of NYSE:NVO opened at $84.36 on Monday. The stock has a market cap of $378.56 billion, a price-to-earnings ratio of 27.30, a PEG ratio of 0.93 and a beta of 0.45. The company has a debt-to-equity ratio of 0.43, a current ratio of 0.94 and a quick ratio of 0.75. Novo Nordisk A/S has a 12 month low of $78.17 and a 12 month high of $148.15. The stock’s 50 day moving average price is $93.56 and its 200 day moving average price is $113.03.

Analysts Set New Price Targets

A number of research analysts have issued reports on NVO shares. Cantor Fitzgerald reissued an “overweight” rating and set a $160.00 target price on shares of Novo Nordisk A/S in a research note on Wednesday, November 6th. StockNews.com downgraded Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a research report on Sunday, December 29th. Sanford C. Bernstein upgraded Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a research report on Monday, January 6th. BMO Capital Markets reduced their price target on Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating for the company in a research report on Monday, December 23rd. Finally, UBS Group raised Novo Nordisk A/S from a “sell” rating to a “buy” rating in a report on Wednesday, January 8th. One research analyst has rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus target price of $145.25.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.